[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "First dose COVID vaccination", "description": "", "link": "https://www.youtube.com/watch?v=LIFqzDQJHuw", "date_published": "2021-01-01 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Vaccines, one shot or two?", "description": "Oxford AZ vaccine\n\nhttps://uk.reuters.com/article/uk-health-coronavirus-india-vaccine/astrazeneca-vaccine-set-to-become-first-to-get-approval-in-india-sources-idUKKBN29628Y\n\nIndia approves Oxford vaccine\n\nIndia\u2019s Central Drugs Standard Control Organization (CDSCO)\n\nRollout to start Wednesday\n\nUK\n\nArgentina\n\nIndia\n\nWhat about Europe and the US?\n\nEurope, 400 million does\n\nUS, 300 million doses\n\n\nOn different topic\n\nhttps://news.sky.com/story/covid-19-vaccines-how-do-the-moderna-and-pfizer-coronavirus-jab-candidates-compare-12134062\n\nhttps://www.businessinsider.com/cost-pfizer-astrazeneca-moderna-vaccine-eu-revealed-belgian-mp-2020-12?r=US&IR=T\n\nOxford AstraZeneca $2.18 per dose\n\nPfizer, $20\n\nModerna, $22.06 to $38 per dose\n\n\nWhere is rollout going well\n\nIsrael, 644,000 or 7% so far\n\nBahrain\n\nUK\n\nUS \n\nCanada\n\nEurope\n\n\nOxford/AstraZeneca vaccine\n\nPhase 2 trials\n\n56-day gap\n\nPhase 3 trials\n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32623-4/fulltext\n\nGood immunity with 6-week gap\n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext\n\nEfficacy after one dose, 64%\n\nEfficacy after 2 doses, 70 \u2013 80%\n\nCases, 21 days after first SD, 64%\n\nVaccine group, 51 \n\nControl group, 141 \n\nEfficacy 64% \n\nSevere cases 21 days after the first dose of Oxford / AZ\n\nVaccine group, 0\n\nControl group, 10 hospitalised (2 severe, 1 death)\n\n\nCovid-19: Pfizer BioNTech vaccine efficacy was 52% after first dose and 95% after second dose\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2034577?query=RP\n\nhttps://www.bmj.com/content/371/bmj.m4826\n\n\nTwelve days after the first dose\n\nVaccine group, 39 cases\n\nPlacebo group, 82 cases\n\n52% efficacy\n\nSevere cases after one dose\n\nVaccine group, 1\n\nPlacebo group, 9\n\nNew UK vaccine protocol\n\nChange to one dose, second within 3 months\n\nStatement from the UK Chief Medical Officers on the prioritisation of first doses of COVID-19 vaccines\n\nhttps://www.gov.uk/government/news/statement-from-the-uk-chief-medical-officers-on-the-prioritisation-of-first-doses-of-covid-19-vaccines\n\nMedicines and Healthcare products Regulatory Agency (MHRA)\n\nOxford, 2 doses 4 to 12 weeks apart\n\nPfizer, 2 doses 3 to 12 weeks apart \n\nThe Joint Committee on Vaccination and Immunisation (JCVI)\n\nwill protect the greatest number of at risk people overall\n\nin the shortest possible time\n\nand will have the greatest impact on reducing mortality, \n\nsevere disease\n\nand hospitalisations\n\nand in protecting the NHS and equivalent health services.\n\nsecond doses of both vaccines will be administered towards the end of the recommended vaccine dosing schedule of 12 weeks\n\nThe Green Book\n\nhttps://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948757/Greenbook_chapter_14a_v4.pdf\n\nIf an interval longer than the recommended interval is left between doses, the second dose should still be given\n(preferably using the same vaccine as was given for the first dose). \nThe course does not need to be restarted. \nThere is no evidence on the interchangeability of the COVID-19 vaccines although studies are underway. \nTherefore, every effort should be made to determine which vaccine the individual received and to complete with the same vaccine. \nThere is no evidence of any safety concerns from vaccinating individuals with a past history of COVID-19 infection, or with detectable COVID-19 antibody.", "link": "https://www.youtube.com/watch?v=M-jqf6i5OLc", "date_published": "2021-01-01 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Cases rise, new variant in US", "description": "UK. Cases, + 50,023 = 2,432,888\nhttps://www.bbc.co.uk/news/explainers-52530518\nhttps://coronavirus.data.gov.uk/details/cases\n\nHospitalised, + 2,430 = 23,771 (ventilated, 1,847)\n\nPrevious peak, 12 April = 21,683\n\nInjections versus infections\n\nVaccinated, 616,933\n\nDeaths, + 981 = 72,548\n\nDeaths, + 3,270 = 82,624\n\nCOVID symptom tracker data\n\nhttps://covid.joinzoe.com\n\nCases, + 55,266 (plus 20%)\n\nVerbier\n\nAbout a dozen British tourists out of about 420 left in resort\n\nSwiss health minister, Alain Berset\n\nWe are aware of that. It\u2019s obviously a problem. There was an order to quarantine that has not been respected\n\nAbout 3,500, from UK to Switzerland for Christmas\n\nVOC Updates\n\nReport 42 - Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data\n\nhttps://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-42-sars-cov-2-variant/\n\nImperial College with MRC for Global Infectious Diseases Analysis\n\nAvailable data indicate a shift in the age composition of reported cases, with a larger share of under 20 year olds among reported VOC than non-VOC cases\n\nLineage-specific growth of SARS-CoV-2 B.1.1.7 during the English national lockdown\n\nhttps://virological.org/t/lineage-specific-growth-of-sars-cov-2-b-1-1-7-during-the-english-national-lockdown/575\n\nB.1.1.7 proliferated in England, 87% (213/244) of lower tier local authorities\n\nAverage R value of 1.25\n\nAt the same time other lineages, R = 0.85 in most regions\n\nLeading to 83% (203/244) of regions showing B.1.1.7 proliferation while other lineages diminished\n\nUnited States\n\nCDC trends (Saturday, 28th December)\n\nhttps://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases\n\nOfficial US hospitalizations\n\nhttps://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html\n\nCases, + 225,671 = 19,493,586\n\nUp 6.9% over past 7 days\n\nHospitalizations, 125,220 (23,069) (7,930)\n\nDeaths, 333,524\n \nhttps://covidtracking.com\n\nVaccinations 2.1 million\n\nOxford/AstraZeneca Covid-19 vaccine, US\n\nhttps://edition.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-12-30-20/h_b62213a48c6b56472475c3ae654bce4d\n\nDr. Moncef Slaoui, chief scientific adviser for Operation Warp Speed\n\nMay be authorized for emergency use in the US in April\n\nSeveral tens of millions should be manufactured in the US by then\n\nVOC spread?\n\nColorado\n\nB.1.1.7, is (VOC), 202012/01 \n\nVariant has 17 mutations, eight alter the spike protein\n\nFirst known cases in the United States\n\nTwo National Guard members\n\nIn isolation in Elbert County\n\nNo travel history, (Gov. Jared Polis)\n\nIndicating likely community spread\n\nContact tracing interviews ongoing\n\nNational Guard, deployed Dec. 23 to the Good Samaritan Society assisted-living facility\n\nAll 26 residents tested positive for the familiar strain of the virus, four died\n\nThe Centers for Disease Control and Prevention\n\ncould lead to more cases and place greater demand on already strained health care resources\n\nSouthern California\n\nhttps://www.washingtonpost.com/health/covid-variant-colorado-second-case/2020/12/30/1605b40a-4abc-11eb-a9f4-0e668b9772ba_story.html\n\nSan Diego County, 30-year-old man, tested Wednesday\n\nNo known travel history\n\nGov. Gavin Newsom\n\nthis new strain that we\u2019ve identified obviously from the United Kingdom \u2026 \n\nCenters for Disease Control and Prevention\n\nNovember, will eventually be able to analyse as many as 3,500 virus genomes per week\n\nFrancis Collins, Director of the National Institutes of Health\n\nIf there was a reason to work really hard on stopping community transmission, we have an even better reason now, because we\u2019re up against a more formidable enemy\n\nThings are getting bad enough already, just from the previous viral strain\n\nIran\n\nHas launched human trials of its first domestic vaccine candidate\n\n65,000 volunteers\n\nTime scale, 45 to 60 days\n\nN = 56\n\nBuying vaccines from the World Health Organization-led Covax alliance\n\nPlanning to import a Chinese vaccine.\n\nDownload my two educational text books for free using this link: http://159.69.48.3\n\nHard copy of the Physiology Notes text book on ebay, https://www.ebay.co.uk/itm/-/15402036...\n\nJohn\u2019s research on text book efficacy, https://journals.sagepub.com/doi/full/10.1177/2158244015612517", "link": "https://www.youtube.com/watch?v=h-sQuJanJSs", "date_published": "2020-12-31 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]